| Literature DB >> 24747968 |
Xia Li1,2, Yuexin Liu1, Kirsi J Granberg1,3,4, Qinhao Wang2, Lynette M Moore1, Ping Ji1, Joy Gumin5, Erik P Sulman6, George A Calin7,8, Hannu Haapasalo4, Matti Nykter3,9, Ilya Shmulevich10, Gregory N Fuller1, Frederick F Lang5, Wei Zhang1,8.
Abstract
MIR-491 is commonly co-deleted with its adjacent CDKN2A on chromosome 9p21.3 in glioblastoma multiforme (GBM). However, it is not known whether deletion of MIR-491 is only a passenger event or has an important role. Small-RNA sequencing of samples from GBM patients demonstrated that both mature products of MIR-491 (miR-491-5p and -3p) are downregulated in tumors compared with the normal brain. The integration of GBM data from The Cancer Genome Atlas (TCGA), miRNA target prediction and reporter assays showed that miR-491-5p directly targets EGFR, CDK6 and Bcl-xL, whereas miR-491-3p targets IGFBP2 and CDK6. Functionally, miR-491-3p inhibited glioma cell invasion; overexpression of both miR-491-5p and -3p inhibited proliferation of glioma cell lines and impaired the propagation of glioma stem cells (GSCs), thereby prolonging survival of xenograft mice. Moreover, knockdown of miR-491-5p in primary Ink4a-Arf-null mouse glial progenitor cells exacerbated cell proliferation and invasion. Therefore, MIR-491 is a tumor suppressor gene that, by utilizing both mature forms, coordinately controls the key cancer hallmarks: proliferation, invasion and stem cell propagation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24747968 PMCID: PMC4205227 DOI: 10.1038/onc.2014.98
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867